Vera Therapeutics VERA
Vera Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$30.94+3.17%close on Oct. 28, 2026 · volume 1.3M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 15, 2026 | Marshall Fordyce PRESIDENT AND CEO, director | Sold 10b5-1 plan | 18,500 | $37.00 | $684,500 |
| Sept. 2, 2026 | Marshall Fordyce PRESIDENT AND CEO, director | Sold 10b5-1 plan | 18,500 | $35.12 | $649,642 |
| July 7, 2026 | Marshall Fordyce PRESIDENT AND CEO, director | Sold 10b5-1 plan amended | 46,250 | $42.30 $40.78-$43.59 | $1.96 million |
| June 23, 2026 | Marshall Fordyce PRESIDENT AND CEO, director | Sold 10b5-1 plan amended | 18,500 | $37.93 $37.93-$38.43 | $701,769 |
| May 12, 2026 | Marshall Fordyce PRESIDENT AND CEO, director | Sold 10b5-1 plan amended | 18,500 | $36.74 $36.64-$37.09 | $679,747 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Regulation FD disclosure · Other events · Financial statements and exhibits